Autonomix Medical, INC. (AMIX) — SEC Filings

Overview

Autonomix Medical, INC. (AMIX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-8 filed on Apr 2, 2026: Autonomix Medical, Inc. filed an S-8 form on April 2, 2026, to register 1,000,000 shares of common stock available for issuance under its 2024 Equity Incentive Plan. This filing makes these shares available for future grants to employees and consultants. The company is based in The Woodlands, TX.

Sentiment Summary

Across 43 filings, the sentiment breakdown is: 1 bullish, 6 bearish, 36 neutral. The dominant filing sentiment for Autonomix Medical, INC. is neutral.

Filing Type Overview

Autonomix Medical, INC. (AMIX) has filed 1 S-8, 20 8-K, 6 10-Q, 3 S-1, 2 DEF 14A, 1 S-1/A, 2 10-K/A, 2 10-K, 3 SC 13G, 1 DEFA14A, 2 SC 13D with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (43)

• Autonomix Medical Files S-8 for 1M Shares — S-8 · Apr 2, 2026 Risk: medium
  Autonomix Medical, Inc. filed an S-8 form on April 2, 2026, to register 1,000,000 shares of common stock available for issuance under its 2024 Equity Incentive
• Autonomix Medical Files 8-K on Agreements and Equity Sales — 8-K · Nov 19, 2025 Risk: medium
  Autonomix Medical, Inc. filed an 8-K on November 19, 2025, reporting on events that occurred on November 18, 2025. The filing indicates the company entered into
• Autonomix Losses Double Amid Soaring R&D, G&A Costs — 10-Q · Nov 12, 2025 Risk: high
  Autonomix Medical, Inc. reported a significant increase in net loss for the three and six months ended September 30, 2025, reaching $7.5 million and $10.8 milli
• 8-K Filing — 8-K · Nov 3, 2025
• Autonomix S-1 Reveals $15M Lincoln Park Equity Line, Going Concern Doubts — S-1 · Sep 23, 2025 Risk: high
  Autonomix Medical, Inc. (AMIX) is a development-stage medical device company focused on a catheter-based technology platform for sensing and treating nervous sy
• Autonomix Seeks Reverse Split, Equity Plan Boost Ahead of Annual Meeting — DEF 14A · Sep 12, 2025 Risk: high
  Autonomix Medical, Inc. (AMIX) is holding its Annual Meeting on October 30, 2025, where stockholders will vote on five key proposals. The company seeks approval
• Autonomix Medical Files S-1/A, Updates Warrants & Executive Pacts — S-1/A · Sep 3, 2025 Risk: medium
  Autonomix Medical, Inc. filed Amendment No. 1 to its S-1 Registration Statement on September 3, 2025, primarily as an exhibits-only filing, indicating no change
• Autonomix Medical Files 8-K — 8-K · Aug 27, 2025 Risk: low
  Autonomix Medical, Inc. filed an 8-K on August 27, 2025, reporting other events and financial statements as of August 25, 2025. The filing does not detail speci
• Autonomix Medical Files 8-K on Agreements and Equity Sales — 8-K · Aug 26, 2025 Risk: medium
  Autonomix Medical, Inc. filed an 8-K on August 25, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and financial st
• Autonomix Medical Files for Potential $500M Offering — S-1 · Aug 20, 2025 Risk: medium
  Autonomix Medical, Inc. filed an S-1 form on August 20, 2025, to register for a proposed offering of 10,000,000 shares of common stock. The company, based in Th
• Autonomix Medical's Losses Widen Amid Increased R&D Spend — 10-Q · Aug 13, 2025 Risk: high
  Autonomix Medical, Inc. (AMIX) reported a net loss of $3.3 million for the three months ended June 30, 2025, an increase from the $2.7 million net loss in the s
• Autonomix Medical Amends 10-K, Confirms Compliance Status — 10-K/A · Jul 28, 2025 Risk: low
  Autonomix Medical, Inc. (AMIX) filed a 10-K/A on July 28, 2025, for the fiscal year ended March 31, 2025, indicating an amendment to its annual report. The fili
• Autonomix Medical Announces Material Definitive Agreement — 8-K · Jul 22, 2025 Risk: medium
  Autonomix Medical, Inc. announced on July 21, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of equ
• Autonomix Medical: Zero Revenue, High Dilution Risks in 10-K — 10-K · May 29, 2025 Risk: high
  Autonomix Medical, Inc. (AMIX) reported no revenue for the fiscal year ended March 31, 2025, continuing its pre-commercialization phase. The company's net incom
• Autonomix Medical Files 8-K — 8-K · Apr 30, 2025 Risk: low
  Autonomix Medical, Inc. filed an 8-K on April 30, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain
• Autonomix Medical Files 8-K for Material Agreement — 8-K · Feb 28, 2025 Risk: medium
  Autonomix Medical, Inc. filed an 8-K on February 28, 2025, reporting the entry into a material definitive agreement. The filing also includes other events and f
• Autonomix Medical Files 10-Q for Q3 2025 — 10-Q · Feb 13, 2025 Risk: medium
  Autonomix Medical, Inc. filed a 10-Q for the period ending December 31, 2024. The company reported a fiscal year end of March 31st and is incorporated in Delawa
• Autonomix Medical Files 8-K — 8-K · Jan 22, 2025 Risk: low
  Autonomix Medical, Inc. filed an 8-K on January 22, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorporated
• SC 13G Filing — SC 13G · Dec 3, 2024
• SC 13G Filing — SC 13G · Nov 27, 2024
• Autonomix Medical Files 8-K for Material Agreement — 8-K · Nov 25, 2024 Risk: medium
  Autonomix Medical, Inc. announced on November 22, 2024, that it entered into a Material Definitive Agreement. The company also reported other events and filed f
• Autonomix Medical Files 8-K on Financials — 8-K · Nov 12, 2024 Risk: low
  Autonomix Medical, Inc. filed an 8-K on November 12, 2024, reporting on its results of operations and financial condition. The filing includes financial stateme
• Autonomix Medical Files 10-Q, Details Offering Probabilities — 10-Q · Nov 8, 2024 Risk: medium
  Autonomix Medical, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported no outstanding or exercisable options in-the-money as of M
• Autonomix Medical to Acquire Neuro-Stim Technologies — 8-K · Nov 4, 2024 Risk: medium
  Autonomix Medical, Inc. announced on November 4, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests of Neuro-Stim
• Autonomix Medical Files for Public Offering — S-1 · Nov 1, 2024 Risk: medium
  Autonomix Medical, Inc. filed an S-1 registration statement on November 1, 2024, to register an unspecified number of securities. The company, incorporated in D
• Autonomix Medical Files 8-K on Security Holder Rights — 8-K · Oct 28, 2024 Risk: medium
  Autonomix Medical, Inc. filed an 8-K on October 28, 2024, reporting material modifications to security holder rights and other events as of October 22, 2024. Th
• Autonomix Medical Files 8-K on Shareholder Votes — 8-K · Oct 17, 2024 Risk: low
  Autonomix Medical, Inc. filed an 8-K on October 17, 2024, to report on matters submitted to a vote of its security holders. The filing details the company's cor
• SC 13G Filing — SC 13G · Oct 7, 2024
• Autonomix Medical Faces Delisting Concerns — 8-K · Sep 20, 2024 Risk: high
  Autonomix Medical, Inc. filed an 8-K on September 20, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's princi
• Autonomix Medical Files Proxy Materials — DEFA14A · Sep 5, 2024 Risk: low
  Autonomix Medical, Inc. filed a Definitive Additional Materials proxy statement on September 5, 2024, related to its 2024 annual meeting. The filing indicates n
• Autonomix Medical Files Definitive Proxy Statement — DEF 14A · Sep 4, 2024 Risk: low
  Autonomix Medical, Inc. filed a definitive proxy statement (DEF 14A) on September 4, 2024, for its annual meeting of stockholders. The filing indicates no fee w
• Autonomix Medical: 5.2M Warrants In-The-Money — 10-Q · Aug 13, 2024 Risk: medium
  Autonomix Medical, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported no revenue for the quarter. As of June 30, 2024, Autonomix Medi
• Autonomix Medical Files 10-K Amendment — 10-K/A · Jul 26, 2024 Risk: low
  Autonomix Medical, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended March 31, 2024. The filing, dated July 26, 2024, provides upd
• Autonomix Medical Files 8-K on Definitive Agreement — 8-K · Jul 15, 2024 Risk: medium
  Autonomix Medical, Inc. entered into a Material Definitive Agreement on July 10, 2024, related to the sale of equity securities. The company also disclosed info
• Autonomix Medical Appoints New CMO, Director — 8-K · Jun 21, 2024 Risk: medium
  Autonomix Medical, Inc. announced on June 21, 2024, the appointment of Dr. David L. Bear as Chief Medical Officer and the election of Ms. Sarah P. Empey to its
• Autonomix Medical Files 8-K — 8-K · Jun 18, 2024 Risk: low
  Autonomix Medical, Inc. filed an 8-K on June 18, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain s
• Autonomix Medical Shuffles Leadership, Appoints New CFO — 8-K · Jun 17, 2024 Risk: medium
  Autonomix Medical, Inc. announced on June 17, 2024, the departure of its Chief Financial Officer, Michael L. Collins. The company also elected new directors and
• Autonomix Medical Files 2024 10-K: Shares, Assets, Liabilities Detailed — 10-K · May 31, 2024 Risk: medium
  Autonomix Medical, Inc. filed its 10-K for the fiscal year ending March 31, 2024, reporting significant financial activities. The company's filing indicates a s
• Autonomix Medical Files 8-K with Corporate Updates — 8-K · Mar 4, 2024 Risk: low
  Autonomix Medical, Inc. filed an 8-K on February 29, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the co
• Landy Toth Files SC 13D on Autonomix Medical Stock — SC 13D · Feb 26, 2024 Risk: medium
  Landy Toth filed a Schedule 13D on February 26, 2024, indicating an event on January 26, 2024, that required the filing. The filing concerns Autonomix Medical,
• Walter Klemp Files Initial 13D on Autonomix Medical, Inc. — SC 13D · Feb 15, 2024 Risk: medium
  Walter V Klemp filed an initial Schedule 13D on February 15, 2024, disclosing an event on January 26, 2024, regarding his beneficial ownership in Autonomix Medi
• Autonomix Medical, Inc. Files 10-Q for Period Ending December 31, 2023 — 10-Q · Feb 13, 2024 Risk:
  Autonomix Medical, Inc. (AMIX) filed a Quarterly Report (10-Q) with the SEC on February 13, 2024. Autonomix Medical, Inc. filed a 10-Q report for the period end
• Autonomix Medical Reports Unregistered Equity Sale on Jan 26 — 8-K · Jan 31, 2024
  Autonomix Medical, Inc. filed an 8-K on January 31, 2024, reporting an unregistered sale of equity securities that occurred on January 26, 2024. This means the

Risk Profile

Risk Assessment: Of AMIX's 37 recent filings, 6 were flagged as high-risk, 20 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Autonomix Medical, INC.'s most recent 10-Q filing (Nov 12, 2025):

• Revenue: $0
• Net Income: -$7.5M
• EPS: -$1.38
• Debt-to-Equity: 0.23
• Cash Position: $7.5M
• Operating Margin: N/A
• Total Assets: $7.9M
• Total Debt: $1.5M

Key Executives

• Brad Hauser
• Cavas S. Pavri
• Johnathan Duncan
• Walter V. Klemp
• Landy Toth
• Trent Smith
• Lori Bisson
• Dr. David L. Bear
• Ms. Sarah P. Empey
• Michael L. Collins
• David L. Smith
• Walter V Klemp

Industry Context

The life sciences industry, particularly the clinical-stage segment, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies in this space often operate at a loss for extended periods, relying heavily on venture capital, public offerings, or strategic partnerships for funding. The competitive landscape is intense, with success dependent on scientific innovation, clinical trial outcomes, and securing intellectual property.

Top Tags

financials (7) · Medical Devices (6) · material-definitive-agreement (4) · filing (4) · 8-k (4) · regulatory-filing (4) · medical-devices (4) · equity-securities (3) · Going Concern (3) · Equity Financing (3)

Key Numbers

• Shares Registered: 1,000,000 — Number of common shares Autonomix Medical is registering for its employee benefit plan.
• Fiscal Year End: 0331 — Indicates the company's financial reporting cycle.
• Net Loss (Q3 2025): $7.5M — Increased from $2.8M in Q3 2024, a 168% increase
• Net Loss (YTD Q3 2025): $10.8M — Increased from $5.5M in YTD Q3 2024, a 96% increase
• Cash and Cash Equivalents: $7.5M — As of September 30, 2025, down from $9.1M on March 31, 2025
• Net Cash Used in Operating Activities (YTD Q3 2025): $6.4M — Increased from $3.4M in YTD Q3 2024
• Accumulated Deficit: $61.2M — As of September 30, 2025, indicating significant historical losses
• Cash Runway Estimate: Q3 2026 — Company estimates cash will fund operations only into this quarter
• Research and Development (Q3 2025): $2.4M — Increased from $1.2M in Q3 2024, a 100% increase
• General and Administrative (Q3 2025): $5.2M — Increased from $1.7M in Q3 2024, a 206% increase
• Shares Outstanding: 6,886,648 — As of November 4, 2025, indicating potential dilution from prior periods
• Net Proceeds from ATM Sales: $2.6M — As of September 30, 2025, from 1,682,685 shares
• Committed Equity Financing: $15.0M — Maximum amount Autonomix Medical may sell to Lincoln Park under the Purchase Agreement
• Total Shares Offered for Resale: 2,500,000 — Aggregate shares of common stock offered for resale by Lincoln Park
• Purchase Shares: 2,238,068 — Shares Autonomix Medical may elect to issue and sell to Lincoln Park

Frequently Asked Questions